Novo Nordisk has launched a price war in the US by offering its weight-loss pill Wegovy at a lower price of $149 a month for the lowest doses in oral form, effective until April. This move is likely to impact the market share of competitors in the weight-loss medication segment. The price cut may also increase demand for Wegovy in the US market.